Form 8-K - Current report:
SEC Accession No. 0001448431-25-000003
Filing Date
2025-05-12
Accepted
2025-05-12 16:08:06
Documents
15
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K oprx-20250512.htm   iXBRL 8-K 26849
2 EX-99.1 oprxq12025earningsrelease.htm EX-99.1 187278
6 picture1a.jpg GRAPHIC 7138
  Complete submission text file 0001448431-25-000003.txt   367954

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oprx-20250512.xsd EX-101.SCH 1791
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oprx-20250512_lab.xml EX-101.LAB 22534
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oprx-20250512_pre.xml EX-101.PRE 13052
17 EXTRACTED XBRL INSTANCE DOCUMENT oprx-20250512_htm.xml XML 3001
Mailing Address 260 CHARLES STREET SUITE 302 WALTHAM MA 02453
Business Address 260 CHARLES STREET SUITE 302 WALTHAM MA 02453 248-651-6558
OptimizeRx Corp (Filer) CIK: 0001448431 (see all company filings)

EIN.: 261265381 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38543 | Film No.: 25934818
SIC: 7389 Services-Business Services, NEC
(CF Office: 07 Trade & Services)